Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

ANDAs Can Get Priority, Eight-Month Reviews Under User Fee Deal

Sep 24 2016

• By Derrick Gingery

PillChart_1200x675

Related Content

ANDA Reviews: First-Cycle Desired, But Two-Cycles OK?

Jul 27 2015

Could Drug Price Spikes Spur ANDA Priority Reviews?

Jan 28 2016

Biosimilar User Fee Agreement Offers FDA Funding Boost, Fee Structure Overhaul

Sep 17 2016

EpiPen Generics: Woodcock Explains Injector Studies

Sep 22 2016

GDUFA II: Priority Reviews Considered For Some ANDAs

Nov 06 2015

FDA To ANDA Sponsors: Don't Forget Quality When Rushing For 10-Month Review Goal

May 17 2016

Generic Drugs 2014: OGD Creates Internal Review Goals, May Make OND-Inspired Changes

Jan 06 2014

Drug Pricing Panacea Or Just PR Victory? Expedited ANDAs May Have Limited Impact

Mar 21 2016

ANDA Approvals, Submissions Decline With New Review Goal Coming

Aug 12 2016

Biosimilar User Fee Agreement Puts FDA On Hook For Delayed Guidances

Sep 22 2016

EpiPen Price Hearing: House Plays Bootleg Tape Of Shkreli Event

Sep 22 2016

Related Companies

Vyera Pharmaceuticals, LLC

Viatris Inc.

Additional Topics

United States Drug Approval Standards Drug Review Regulation BioPharmaceutical

More from Approval Standards

More from Pathways & Standards

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window